How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?

@article{Zhou2004HowOD,
  title={How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?},
  author={Ming Zhou and Hakan Aydin and Hillel Kanane and Jonathan I. Epstein},
  journal={The American journal of surgical pathology},
  year={2004},
  volume={28 2},
  pages={239-43}
}
BACKGROUND Alpha-methylacyl-CoA-racemase (AMACR), a recently discovered tumor marker for prostate cancer, is being used increasingly in conjunction with hematoxylin and eosin (H&E) histology and basal cell markers in the workup of difficult prostate needle biopsies. However, it is not known how often a positive AMACR staining is used merely to support a malignant diagnosis that could otherwise be established based on routine H&E histology and negative basal cell staining. METHODS This study… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…